BA3361 / BioAtla - LARVOL DELTA

BA3361, a tumor selective, conditionally active biologic (CAB) anti-nectin4-ADC with a novel NextGen linker system enhances therapeutic efficacy in pancreatic cancer (AACR 2025) - "In conclusion, our NextGen Nectin4-CAB-ADC BA3361 demonstrates comparable or superior activity in lung, breast, and urothelial patient derived cancer models compared to Enfortumab vedotin and outperforms it in pancreatic PDX models. In addition, the conditional binding in the TME should help to reduce side effects of nonCAB ADCs and potentially widen the therapeutic index."

Clinical • Oncology • Pancreatic Cancer • Solid Tumor • NECTIN4

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "BioAtla...announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research (AACR)....Two abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology. Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in lung, breast, pancreatic and urothelial patient derived cancer models."

Preclinical • Breast Cancer • Lung Cancer • Pancreatic Cancer • Urothelial Cancer

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors (GlobeNewswire) - "BioAtla, Inc...announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3361 (CAB-Nectin-4) antibody drug conjugate (ADC) for the treatment of multiple tumor types,"

IND • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) - "Anti-Nectin-4-ADC (BA3361): In vitro and in vivo characterization of a novel NextGen linker system yields differentiated anti-Nectin-4-ADC. Data to be presented at upcoming AACR Annual Meeting in April: (i) Complete tumor regression observed in several cell line derived xenograft models; (ii) Superior efficacy to an enfortumab vedotin analogue in a patient-derived xenograft pancreatic cancer model; (iii) Demonstrated influence of linker technology on specific cancer models and reduced toxicity through CAB selectivity. IND submission anticipated in 2Q 2024."

IND • Preclinical • Pancreatic Cancer

NextGen conditionally active biologic (CAB) anti-Nectin-4-ADC with improved stability and safety (AACR 2023) - "Two CAB-ADCs (Mecbotamab Vedotin and Ozuriftamab Vedotin) using the well-established vedotin linker with MMAE as payload are currently in phase 2 clinical trials and show promising results with increased safety profiles, with currently no signs of on-target, off-tumor toxicity. BA3361, a CAB-ADC targeting Nectin-4, showed good in vitro and in vivo efficacy data demonstrating cytotoxicity against human Nectin-4-expressing tumor cell lines and tumor regression in xenograft models using the vedotin linker (AACR 2020, Poster #4560)...In vivo efficacy data from CDX models as well as data from non-GLP tox studies in rats and cynomolgus monkeys will be presented. In conclusion, our data indicates that the CAB-Nectin-4-ADC with its optimized linker payload, has superior serum stability while maintaining the CAB target selectivity."

Clinical • Oncology • NECTIN4